Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash & Equivalents: 2013-2024

Historic Cash & Equivalents for KalVista Pharmaceuticals (KALV) over the last 9 years, with Apr 2024 value amounting to $31.8 million.

  • KalVista Pharmaceuticals' Cash & Equivalents was N/A to $182.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $182.3 million, marking a year-over-year change of. This contributed to the annual value of $31.8 million for FY2024, which is N/A change from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Cash & Equivalents stood at $31.8 million for FY2024, which was up 101.34% from $15.8 million recorded in FY2020.
  • In the past 5 years, KalVista Pharmaceuticals' Cash & Equivalents registered a high of $31.8 million during FY2024, and its lowest value of $15.8 million during FY2020.
  • Moreover, its 1-year median value for Cash & Equivalents was $31.8 million (2024), whereas its average is $31.8 million.
  • Data for KalVista Pharmaceuticals' Cash & Equivalents shows a maximum YoY plummeted of 50.67% (in 2020) over the last 5 years.
  • KalVista Pharmaceuticals' Cash & Equivalents (Yearly) stood at $15.8 million in 2020, then followed by $31.8 million in 2024.